Work

Upfront Osimertinib Alone vs. Osimertinib and Radiotherapy for the Treatment of EGFR-Positive NSCLC Brain Metastases: A Multi-Institutional Series

Year: 2023

Type: article

Study design: Observational Study

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2023.06.869

Authors: A.E. Dohm, R. Upadhyay, J.D. Tang, D.E. Oliver, B.A. Perez, S.A. Rosenberg, H.H.M. Yu, J.D. Palmer, S. Beyer, D. Owen, K.A. Ahmed

Institutions: Moffitt Cancer Center, The Ohio State University Wexner Medical Center, The Ohio State University

Language: English

Topic: Brain Metastases and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4387206472

FWCI: 0.161

Cites:

Cited by: 1

Related to: 10